Feng JingQi, Gulati Upma, Zhang Xiaoju, Keitel Wendy A, Thompson David M, James Judith A, Thompson Linda F, Air Gillian M
Department of Biochemistry & Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73126-0901, USA.
Vaccine. 2009 Oct 23;27(45):6358-62. doi: 10.1016/j.vaccine.2009.06.090.
The correlates for protection against influenza infection are incompletely characterized. We have applied an ELISA strategy that distinguishes antibodies against native viral surface antigens (potentially neutralizing) from antibodies directed against internal and denatured viral proteins (not neutralizing) to three groups of vaccinated subjects: (1) participants in a study of repeated annual vaccination, (2) elderly subjects and (3) patients with Systemic Lupus Erythematosus compared to control subjects. Antibody increase after vaccination was inversely related to the level of pre-existing antibodies in all groups; most subjects had significant initial antibody levels and showed little increase in amount of antibody after vaccination, but the avidity of their serum antibodies tended to increase. Antibodies against denatured virus proteins varied with vaccine formulation; vaccines that are more recent have less total protein for the same amount of native hemagglutinin. We propose an index consisting of rank order of antibody level plus antibody avidity, both measured against native virus, plus hemagglutination-inhibition antibody titer, as a useful measure of immunity against influenza.
针对流感感染的保护性相关因素尚未完全明确。我们采用了一种酶联免疫吸附测定（ELISA）策略，该策略可区分针对天然病毒表面抗原（可能具有中和作用）的抗体与针对内部和变性病毒蛋白（无中和作用）的抗体，并将其应用于三组接种疫苗的受试者：（1）参与年度重复接种研究的参与者，（2）老年受试者，以及（3）系统性红斑狼疮患者，并与对照组受试者进行比较。在所有组中，接种疫苗后抗体增加与预先存在的抗体水平呈负相关；大多数受试者初始抗体水平较高，接种疫苗后抗体量增加很少，但他们血清抗体的亲和力往往会增加。针对变性病毒蛋白的抗体因疫苗配方而异；对于相同量的天然血凝素，较新的疫苗总蛋白含量较低。我们提出一个指数，该指数由抗体水平的排序加上抗体亲和力（均针对天然病毒进行测量）再加上血凝抑制抗体滴度组成，作为衡量流感免疫力的有用指标。
